Drug Patents Expiring in 2035

1. Drug name - ABSORICA LD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin May, 2035

(12 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin Aug, 2035

(12 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG CAPSULE;ORAL Prescription
16MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Discontinued
24MG CAPSULE;ORAL Prescription
28MG CAPSULE;ORAL Discontinued
32MG CAPSULE;ORAL Prescription

2. Drug name - ACCRUFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(13 years from now)

CN107001310A SHIELD TX Crystalline Form Of Iron Maltol
Oct, 2035

(13 years from now)

CN107001310B SHIELD TX Crystalline Form Of Iron Maltol
Oct, 2035

(13 years from now)

EP3160951A1 SHIELD TX Crystalline Forms Of Ferric Maltol
Oct, 2035

(13 years from now)

EP3160951B1 SHIELD TX Crystalline Forms Of Ferric Maltol
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10179120 SHIELD TX Dosage regimen of ferric trimaltol Jan, 2035

(12 years from now)

Drugs and Companies using FERRIC MALTOL ingredient

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG IRON CAPSULE;ORAL Prescription

3. Drug name - ADHANSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
35MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
45MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
55MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
70MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
85MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

4. Drug name - ADRENALIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657 PAR STERILE PRODUCTS Epinephrine formulations Mar, 2035

(12 years from now)

US9119876 PAR STERILE PRODUCTS Epinephrine formulations Mar, 2035

(12 years from now)

US10130592 PAR STERILE PRODUCTS Epinephrine formulations Mar, 2035

(12 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS Prescription

5. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415008

(Pediatric)

TEVA PHARM Dry powder inhaler Apr, 2035

(12 years from now)

US9066957

(Pediatric)

TEVA PHARM Dry powder inhaler Apr, 2035

(12 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Dec, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

6. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(13 years from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(13 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(13 years from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription

7. Drug name - ALECENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose Apr, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Prescription

8. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(13 years from now)

CN107108559B TAKEDA PHARMS USA 5 - -N4-(2 -) (Dimethyl Phosphoryl) Phenyl] -N2-(2 - -4-(4 - (4 --- Yl)--- Piperazin - -1 - Piperidin - -1 - Yl] - Phenyl) - Pyrimidine - -2, 4 - - Diamine Crystalline Form
Oct, 2035

(13 years from now)

CN107108559A TAKEDA PHARMS USA 5 - -N4-(2 - (- Dimethyl) Phenyl] -N2-(2-Methoxy - -4-[4 - (4-Methylpiperazine - -1 - Yl)--1 - Group]--2, 4-Diamine In Crystalline Form
Oct, 2035

(13 years from now)

EP3209647A1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

EP3209647B1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

9. Drug name - ARAKODA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects Dec, 2035

(13 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects Dec, 2035

(13 years from now)

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription

10. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections May, 2035

(12 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections May, 2035

(12 years from now)

US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections May, 2035

(12 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

11. Drug name - ARISTADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526726 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US9452131 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US10238651 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

US10813928 ALKERMES INC Aripiprazole formulations having increased injection speeds Mar, 2035

(12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
441MG/1.6ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
662MG/2.4ML (275.83MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
882MG/3.2ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1064MG/3.9ML (272.82MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

12. Drug name - ARISTADA INITIO KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154552 ALKERMES INC Aripiprazole prodrug composition Aug, 2035

(12 years from now)

US10849894 ALKERMES INC Aripiprazole prodrug composition Aug, 2035

(12 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition Aug, 2035

(12 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions Sep, 2035

(12 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
675MG/2.4ML SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

13. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Dec, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

14. Drug name - AXUMIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer Dec, 2035

(13 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
9-221mCi/ML SOLUTION;INTRAVENOUS Prescription

15. Drug name - BAFIERTAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326965 BANNER LIFE SCIENCES Controlled release fumarate esters Feb, 2035

(12 years from now)

US9326947 BANNER LIFE SCIENCES Controlled release fumarate esters Feb, 2035

(12 years from now)

US10105335 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US9517209 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US9820960 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US10105337 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US9636319 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US9566259 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US10098863 BANNER LIFE SCIENCES Fumarate esters Feb, 2035

(12 years from now)

US9820961 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US10105336 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US9814691 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US9814692 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US9511043 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Feb, 2035

(12 years from now)

US9636318 BANNER LIFE SCIENCES Fumarate ester dosage forms Feb, 2035

(12 years from now)

US10918616 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Jun, 2035

(12 years from now)

US10918617 BANNER LIFE SCIENCES Fumarate ester pharmaceutical compositions Aug, 2035

(12 years from now)

US10918615 BANNER LIFE SCIENCES Fumarate esters Aug, 2035

(12 years from now)

US10945985 BANNER LIFE SCIENCES Fumarate ester dosage forms Aug, 2035

(12 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
95MG CAPSULE, DELAYED RELEASE;ORAL Prescription

16. Drug name - BALVERSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators Mar, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

17. Drug name - BIKTARVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(12 years from now)

CN106459085A GILEAD SCIENCES INC (2R, 5S, 13Ar) -7, 9 - -10-((2, 4, 6-Trifluoro-Benzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A - -2, 5-Pyridine Methylene Bridge (1 ', 2 ': 4, 5] Pyridine [2, 1-B] [1, 3] * -8 - Sodium Phenolate
Jun, 2035

(12 years from now)

CN106459085B GILEAD SCIENCES INC An Anti-Hiv Compound And Its Crystal
Jun, 2035

(12 years from now)

EP3157932B1 GILEAD SCIENCES INC Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate
Jun, 2035

(12 years from now)

EP3157932A1 GILEAD SCIENCES INC Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Jun, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE;120MG;EQ 15MG BASE TABLET;ORAL Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE TABLET;ORAL Prescription

18. Drug name - BREXAFEMME

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(12 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078 Jan, 2035

(12 years from now)

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

19. Drug name - BUNAVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522188 BDSI Abuse resistant transmucosal drug delivery device Apr, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

20. Drug name - CALQUENCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor Jan, 2035

(12 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

21. Drug name - CINVANTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953018 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
130MG/18ML (7.2MG/ML) EMULSION;INTRAVENOUS Prescription

22. Drug name - CYCLOPHOSPHAMIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662342 EUGIA PHARMA SPECLTS Formulations of cyclophosphamide liquid concentrate Jun, 2035

(12 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/5ML (200MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/2.5ML (200MG/ML) SOLUTION;INTRAVENOUS Prescription

23. Drug name - DAYVIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia Oct, 2035

(13 years from now)

Drugs and Companies using LEMBOREXANT ingredient

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

24. Drug name - DEFINITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(13 years from now)

CN107206111B LANTHEUS MEDCL Lipid Encapsulated Gas Microsphere Compositions And Related Methods
Dec, 2035

(13 years from now)

CN107206111A LANTHEUS MEDCL Gas Microsphere Composition Of Lipid Encapsulation And Related Method
Dec, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods Dec, 2035

(13 years from now)

Drugs and Companies using PERFLUTREN ingredient

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6.52MG/ML INJECTABLE;INTRAVENOUS Prescription

25. Drug name - EPIDIOLEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11096905 GW RES LTD Use of cannabinoids in the treatment of epilepsy
Oct, 2035

(13 years from now)

EP3206716B1 GW RES LTD Use Of Cannabinoids In The Treatment Of Atonic Seizures In Lennox-Gastaut Syndrome
Oct, 2035

(13 years from now)

EP3206716A1 GW RES LTD Use Of Cannabinoids In The Treatment Of Atonic Seizures In Lennox-Gastaut Syndrome
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10709674 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US9956186 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10092525 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US9956183 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US9949937 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10111840 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10137095 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10603288 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10709671 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US9956184 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US9956185 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10849860 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10966939 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10709673 GW RES LTD Use of cannabinoids in the treatment of epilepsy Jun, 2035

(12 years from now)

US10918608 GW RES LTD Use of cannabidiol in the treatment of epilepsy Oct, 2035

(13 years from now)

US11065209 GW RES LTD Use of cannabidiol in the treatment of epilepsy Oct, 2035

(13 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: Use for the treatment of seizures in patients with dravet syndrome; use for the treatment of seizures in patients with lennox-gastaut syndrome; Use for the treatment of convulsive seizures in patients with lennox gastaut syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; Use in combination with clobazam for the treatment of seizures in patients with lennox gastaut syndrome who have been previously treated with clobazam; use in combination with clobazam for the treatment of seizures in patients with dravet syndrome who have been previously treated with clobazam; Use in combination with clobazam for the treatment of seizures in patients with dravet syndrome; Use for the treatment of atonic seizures in patients with dravet syndrome; use for the treatment of atonic seizures in patients with lennox-gastaut syndrome; Use for the treatment of drop seizures in patients with lennox-gastaut syndrome; use in combination with clobazam for treatment of drop seizures in patients with lennox gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; use for reducing convulsive seizure frequency in patients with lennox gastaut syndrome; use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of focal seizures in patients with dravet syndrome; Use in combination with clobazam for treatment of seizures in patients with lennox gastaut syndrome; Use for the treatment of convulsive seizures in patients with dravet syndrome; Use for the treatment of drop seizures in patients with dravet syndrome; use for the treatment of drop seizures in patients with lennox-gastaut syndrome; Use for the treatment of seizures in patients with lennox-gastaut syndrome; use for the treatment of seizures in patients with dravet syndrome; Use for the treatment of generalized seizures or focal seizures with impairment in patients with tuberous sclerosis complex; use for the treatment of seizures in patients with tuberous sclerosis complex; use for reducing seizure frequency in patients with tuberous sclerosis complex; Use for the treatment of seizures in patients with tuberous sclerosis complex

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SOLUTION;ORAL Prescription

26. Drug name - ESKATA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980983 ACLARIS Peroxide formulations and methods and applicators for using the same Apr, 2035

(12 years from now)

US10493103 ACLARIS Peroxide formulations and methods and applicators for using the same Apr, 2035

(12 years from now)

US10729720 ACLARIS Peroxide formulations and methods and applicators for using the same Apr, 2035

(12 years from now)

US10098910 ACLARIS Peroxide formulations and methods and applicators for using the same Apr, 2035

(12 years from now)

US9675639 ACLARIS Peroxide formulations and methods and applicators for using the same Jul, 2035

(12 years from now)

Drugs and Companies using HYDROGEN PEROXIDE ingredient

Treatment: Treatment of seborrheic keratoses that are raised

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
40% SOLUTION;TOPICAL Discontinued

27. Drug name - EVRYSDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

CN106459092B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

CN106459092A GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN201647038542A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN334397B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP3143025B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP3143025A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

Drugs and Companies using RISDIPLAM ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.75MG/ML FOR SOLUTION;ORAL Prescription

28. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

29. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220158 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of a delivery device to deliver a bioequivalent dose of a naloxone composition via a needle

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

30. Drug name - EXEM FOAM KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259494 GISKIT Composition and method for medical imaging of body cavities May, 2035

(12 years from now)

Drugs and Companies using AIR POLYMER-TYPE A ingredient

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
10ML FOAM;INTRAUTERINE Prescription

31. Drug name - EXKIVITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

CN106559991B TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

CN106559991A TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A4 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription

32. Drug name - FETROJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(12 years from now)

CN106795176B SHIONOGI INC Salts Of Cephalosporin Derivatives, Crystalline Solid Thereof, And Process For Producing The Same
Sep, 2035

(12 years from now)

CN106795176A SHIONOGI INC Salt Of Cephalosporin Derivatives, Its Crystalline Solid And Its Manufacturing Method
Sep, 2035

(12 years from now)

EP3190115B1 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

EP3190115A4 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

EP3190115A1 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety Sep, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL POWDER;INTRAVENOUS Prescription

33. Drug name - FINTEPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331 ZOGENIX INC Control system for control of distribution of medication Sep, 2035

(13 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

34. Drug name - FIRVANQ KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959949 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959948 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid Mar, 2035

(12 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Treatment: Treatment of c. difficile-associated diarrhea; treatment of staphylococcal enterocolitis; Treatment of staphylococcal enterocolitis; treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE/ML FOR SOLUTION;ORAL Prescription
EQ 50MG BASE/ML FOR SOLUTION;ORAL Prescription

35. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737051 VERO BIOTECH Nitrogen dioxide storage device Oct, 2035

(13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

36. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment Jul, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment Aug, 2035

(12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

37. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376487 VANDA PHARMS INC Method of treatment Jul, 2035

(12 years from now)

US10179119 VANDA PHARMS INC Method of treatment Aug, 2035

(12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

38. Drug name - ILLUCCIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 TELIX Kit for radiolabelling Jul, 2035

(12 years from now)

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6.7mCi/ML POWDER;INTRAVENOUS Prescription

39. Drug name - IMPOYZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855334 PRIMUS PHARMS Topical compositions comprising a corticosteroid Mar, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
0.025% CREAM;TOPICAL Prescription

40. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer Feb, 2035

(12 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

41. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143680 RECORDATI RARE Pharmaceutical dosage forms Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms Oct, 2035

(13 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

42. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478601 BAUSCH Applicator Apr, 2035

(12 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

43. Drug name - KAPSPARGO SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504655 SPIL Capsule dosage form of metoprolol succinate Jul, 2035

(12 years from now)

US9700530 SPIL Capsule dosage form of metoprolol succinate Jul, 2035

(12 years from now)

Drugs and Companies using METOPROLOL SUCCINATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG TARTRATE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 50MG TARTRATE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 100MG TARTRATE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 200MG TARTRATE CAPSULE, EXTENDED RELEASE;ORAL Prescription

44. Drug name - KENGREAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700575 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same Jul, 2035

(12 years from now)

US9295687 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same Jul, 2035

(12 years from now)

US10039780 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same Jul, 2035

(12 years from now)

US9439921 CHIESI Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same Jul, 2035

(12 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

45. Drug name - KIMYRSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

IN201717005135A MELINTA THERAP High Purity Oritavancin And Method Of Producing Same
Jul, 2035

(12 years from now)

IN359618B MELINTA THERAP High Purity Oritavancin And Method Of Producing Same
Jul, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1.2GM BASE/VIAL POWDER;INTRAVENOUS Prescription

46. Drug name - LENVIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

CN106660964A EISAI INC Quinoline Derivative With High Purity And Production Method Thereof
Aug, 2035

(12 years from now)

CN106660964B EISAI INC High Purity Quinoline Derivatives And Process For Producing The Same
Aug, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription

47. Drug name - LOKELMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(13 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
5GM/PACKET FOR SUSPENSION;ORAL Prescription
10GM/PACKET FOR SUSPENSION;ORAL Prescription

48. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376661 SUNOVION RESP Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element Sep, 2035

(12 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

49. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48923

(Pediatric)

ABBVIE INC Crystal forms Nov, 2035

(13 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms Dec, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;20MG/PACKET PELLETS;ORAL Prescription

50. Drug name - NARCAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629965 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9468747 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US10085937 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9480644 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9775838 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9561177 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9707226 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

US9211253 EMERGENT Nasal drug products and methods of their use Mar, 2035

(12 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
2MG/SPRAY SPRAY, METERED;NASAL Discontinued
4MG/SPRAY SPRAY, METERED;NASAL Prescription

51. Drug name - NITYR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE PHARMS LTD Pharmaceutical composition Jan, 2035

(12 years from now)

Drugs and Companies using NITISINONE ingredient

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

52. Drug name - OBREDON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9808431 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(13 years from now)

US10105324 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(13 years from now)

US9549907 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
200MG/5ML;2.5MG/5ML SOLUTION;ORAL Discontinued

53. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease May, 2035

(12 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

54. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

CN107106874B ALNYLAM PHARMS INC Method For Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

CN107106874A ALNYLAM PHARMS INC Method Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957A4 ALNYLAM PHARMS INC Methods Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957A2 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957B1 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

55. Drug name - ORBACTIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649352 MELINTA THERAP High purity oritavancin and method of producing same Jul, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE/VIAL POWDER;INTRAVENOUS Prescription

56. Drug name - ORLADEYO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(12 years from now)

CN106257976B BIOCRYST Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

CN106257976A BIOCRYST Human Plasma Kallikrein Inhibitor
Mar, 2035

(12 years from now)

EP3113772A4 BIOCRYST Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772A1 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772B8 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772B1 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors Mar, 2035

(12 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors Mar, 2035

(12 years from now)

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

57. Drug name - OTIPRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220796 ALK ABELLO Sterilization of ciprofloxacin composition Jul, 2035

(12 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage
Strength Dosage Availability
6% (60MG/ML) INJECTABLE, SUSPENSION;OTIC Prescription

58. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

EP3102208A4 GLOBAL BLOOD THERAPS Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

EP3102208B1 GLOBAL BLOOD THERAPS Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

EP3102208A1 GLOBAL BLOOD THERAPS Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Feb, 2035

(12 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET;ORAL Prescription

59. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(13 years from now)

CN108064154A ALNYLAM PHARMS INC Composition And Method For Inhibiting Hao1 (Hydroxy Acid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

CN108064154B ALNYLAM PHARMS INC Composition And Method For Inhibiting Expression Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene
Oct, 2035

(13 years from now)

IN372206B ALNYLAM PHARMS INC Double-Stranded Rnai Agents And Compositions For Inhibiting Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

IN201747014263A ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015A4 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

60. Drug name - PEMAZYRE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
4.5MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
13.5MG TABLET;ORAL Prescription

61. Drug name - PEMFEXY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(13 years from now)

Drugs and Companies using PEMETREXED ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/20ML (25MG/ML) SOLUTION;INTRAVENOUS Prescription

62. Drug name - PONVORY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist Dec, 2035

(13 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

63. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Aug, 2035

(12 years from now)

US10918816 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler Dec, 2035

(13 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

64. Drug name - QBRELIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940177 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9463183 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10265370 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10406199 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US10039800 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9616096 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US9814751 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

US11179434 AZURITY Lisinopril formulations Nov, 2035

(13 years from now)

Drugs and Companies using LISINOPRIL ingredient

Treatment: Treatment of myocardial infarction; method of treating hypertension; treatment of heart failure; method of treatment of heart failure; reduction of mortality in acute myocardial infarction; treatment of hypertension; acute myocardial infarction; Acute myocardial infarction; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; method of treatment of heart failure; treatment of heart failure; treatment of hypertension; method of treating hypertension; Treatment of hypertension; method of treating hypertension; treatment of heart failure; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; acute myocardial infarction; method of treatment of heart failure

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
1MG/ML SOLUTION;ORAL Prescription

65. Drug name - QULIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds Jan, 2035

(12 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

66. Drug name - RHOFADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

67. Drug name - RIOMET ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962336 SUN PHARM Extended release suspension compositions May, 2035

(12 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
500MG/5ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Discontinued

68. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells Feb, 2035

(12 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma Feb, 2035

(12 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

69. Drug name - RUBRACA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987285 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib Aug, 2035

(12 years from now)

US10130636 CLOVIS ONCOLOGY INC High dosage strength tablets of rucaparib Aug, 2035

(12 years from now)

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; a method for treating ovarian cancer by administering rucaparib, wherein the cancer is associated with a deleterious brca mutation; a method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 250MG BASE TABLET;ORAL Prescription
EQ 300MG BASE TABLET;ORAL Prescription

70. Drug name - SOLOSEC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis Sep, 2035

(12 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis Sep, 2035

(12 years from now)

Drugs and Companies using SECNIDAZOLE ingredient

Treatment: Treatment of bacterial vaginosis in adult women; treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; treatment of bacterial vaginosis in female patients 12 years of age and older; treatment of trichomoniasis in adults; treatment of bacterial vaginosis in adult women

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
2GM/PACKET GRANULE;ORAL Prescription

71. Drug name - SOTYLIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724297 ARBOR PHARMS LLC Sotalol compositions and uses of the same Aug, 2035

(12 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML (5MG/ML) SOLUTION;ORAL Prescription

72. Drug name - SPINRAZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10436802 BIOGEN IDEC Methods for treating spinal muscular atrophy Sep, 2035

(12 years from now)

Drugs and Companies using NUSINERSEN SODIUM ingredient

Treatment: Treatment of type iii spinal muscular atrophy; treatment of spinal muscular atrophy; treatment of infantile-onset spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) SOLUTION;INTRATHECAL Prescription

73. Drug name - SPRAVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869844 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 28MG BASE SPRAY;NASAL Prescription

74. Drug name - SPY AGENT GREEN KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10631746 NOVADAQ TECH Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography Aug, 2035

(12 years from now)

Drugs and Companies using INDOCYANINE GREEN ingredient

Treatment: Measuring time-varying change in blood in a tissue volume using modified beer-lambert law in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including minimally invasive, surgery

Dosage: POWDER;INTRAVENOUS, INTERSTITIAL

More Information on Dosage
Strength Dosage Availability
25MG/VIAL POWDER;INTRAVENOUS, INTERSTITIAL Prescription

75. Drug name - SUBLOCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000520 INDIVIOR INC Buprenorphine dosing regimens Nov, 2035

(13 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
100MG/0.5ML (100MG/0.5ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
300MG/1.5ML (200MG/ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

76. Drug name - SYMDEKO (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206877 VERTEX PHARMS INC Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases Apr, 2035

(12 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG;75MG, 50MG TABLET;ORAL Prescription
150MG;150MG, 100MG TABLET;ORAL Prescription

77. Drug name - TABRECTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(12 years from now)

EP3172209A1 NOVARTIS PHARM Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide
Jul, 2035

(12 years from now)

EP3172209B1 NOVARTIS PHARM Tablet Formulation Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Ylmethyl)Imidazo[1,2-B][1,2,4]Triazin-2-Yl]Benzamide
Jul, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

78. Drug name - TAGRISSO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291 Jan, 2035

(12 years from now)

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription
EQ 80MG BASE TABLET;ORAL Prescription

79. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10369155 EPIZYME INC Method for treating cancer Oct, 2035

(13 years from now)

US9889138 EPIZYME INC Method for treating cancer Oct, 2035

(13 years from now)

US10786511 EPIZYME INC Method for treating cancer Dec, 2035

(13 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating epithelioid sarcoma; method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; method of treating relapsed or refractory follicular lymphoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

80. Drug name - TECFIDERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10994003 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US10555993 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US10391160 BIOGEN INC Dimethyl fumarate and vaccination regimens Mar, 2035

(12 years from now)

US11007166 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US11129806 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US10959972 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

US11007167 BIOGEN INC Methods of treating multiple sclerosis Nov, 2035

(13 years from now)

Drugs and Companies using DIMETHYL FUMARATE ingredient

Treatment: Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine; Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
120MG CAPSULE, DELAYED RELEASE;ORAL Prescription
240MG CAPSULE, DELAYED RELEASE;ORAL Prescription

81. Drug name - TIBSOVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968595 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

US10799490 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

US10449184 SERVIER Pharmaceutical compositions of therapeutically active compounds Mar, 2035

(12 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); a method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; a method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MG TABLET;ORAL Prescription

82. Drug name - TRIKAFTA (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10758534 VERTEX PHARMS INC NA
Oct, 2035

(13 years from now)

CN107690281B VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Transduction Regulatory Factor
Oct, 2035

(13 years from now)

CN107690281A VERTEX PHARMS INC Cystic Fibrosis Transmembrane Transduction Regulatory Factor Regulator
Oct, 2035

(13 years from now)

EP3203840A1 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

EP3203840B1 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

EP3203840A4 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

More Information on Dosage
Strength Dosage Availability
50MG,37.5MG,25MG; 75MG TABLET;ORAL Prescription
100MG,75MG,50MG; 150MG TABLET;ORAL Prescription

83. Drug name - TYRVAYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597284 OYSTER POINT PHARMA Dry eye treatments Oct, 2035

(13 years from now)

US10456396 OYSTER POINT PHARMA Dry eye treatments Oct, 2035

(13 years from now)

US9504645 OYSTER POINT PHARMA Pharmaceutical formulations for treating ocular conditions Oct, 2035

(13 years from now)

US11224598 OYSTER POINT PHARMA Methods of increasing lacrimal proteins Oct, 2035

(13 years from now)

US9504644 OYSTER POINT PHARMA Methods of increasing tear production Oct, 2035

(13 years from now)

US9532944 OYSTER POINT PHARMA Methods of improving ocular discomfort Oct, 2035

(13 years from now)

Drugs and Companies using VARENICLINE TARTRATE ingredient

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 0.03MG BASE/SPRAY SOLUTION;NASAL Prescription

84. Drug name - UBRELVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ALLERGAN Tablet formulation for CGRP active compounds Jan, 2035

(12 years from now)

Drugs and Companies using UBROGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

85. Drug name - UKONIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414773 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

US9969740 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

CN106661030B TG THERAPS Improved Form For Pharmaceutical Preparation Of Pi3K Inhibitors
May, 2035

(12 years from now)

CN106661030A TG THERAPS Improved Form For Pi3K Selective Inhibitor In The Pharmaceutical Formulation
May, 2035

(12 years from now)

IN328766B TG THERAPS Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

IN201647042988A TG THERAPS Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

EP3149000A1 TG THERAPS Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

EP3149000B1 TG THERAPS Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10947244 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations May, 2035

(12 years from now)

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

86. Drug name - VANCOMYCIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

US10039804 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

US11000567 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

US10849956 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

Drugs and Companies using VANCOMYCIN ingredient

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS, ORAL

More Information on Dosage
Strength Dosage Availability
5GM/100ML (50MG/ML) SOLUTION;INTRAVENOUS, ORAL Prescription

87. Drug name - VANCOMYCIN HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

US10039804 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

US10849956 XELLIA PHARMS APS Glycopeptide compositions Nov, 2035

(13 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/200ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2GM BASE/400ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 500MG BASE/100ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 750MG BASE/150ML (EQ 5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

88. Drug name - VASOSTRICT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744239 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9750785 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9925233 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9925234 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9962422 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9968649 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9974827 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9981006 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US10010575 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9937223 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9687526 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9744209 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9375478 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

US9919026 PAR STERILE PRODUCTS Vasopressin formulations for use in treatment of hypotension Jan, 2035

(12 years from now)

Drugs and Companies using VASOPRESSIN ingredient

Treatment: To increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
20UNITS/ML (20UNITS/ML) SOLUTION;INTRAVENOUS Prescription
20UNITS/100ML (0.2UNITS/ML) SOLUTION;INTRAVENOUS Prescription
40UNITS/100ML (0.4UNITS/ML) SOLUTION;INTRAVENOUS Prescription
60UNITS/100ML (0.6UNITS/ML) SOLUTION;INTRAVENOUS Prescription
200UNITS/10ML (20UNITS/ML) SOLUTION;INTRAVENOUS Prescription

89. Drug name - VEKLURY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(13 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(13 years from now)

CN107073005B GILEAD SCIENCES INC Method Of Treating A Virus Infection In A Filamentous Virus
Oct, 2035

(13 years from now)

CN107073005A GILEAD SCIENCES INC Method Of Treating Filamentous Virus Family Virus Infections
Oct, 2035

(13 years from now)

EP3212175A1 GILEAD SCIENCES INC Methods For The Preparation Of Ribosides
Oct, 2035

(13 years from now)

EP3366295B1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3212174A1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3366295A1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3212175B1 GILEAD SCIENCES INC Methods For The Preparation Of Ribosides
Oct, 2035

(13 years from now)

EP3212174B1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

Drugs and Companies using REMDESIVIR ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

90. Drug name - VELPHORO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624855

(Pediatric)

VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles May, 2035

(12 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 500MG IRON TABLET, CHEWABLE;ORAL Prescription

91. Drug name - VIEKIRA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744170 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

US10105365 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

US9333204 ABBVIE INC Solid antiviral dosage forms Jan, 2035

(12 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE;8.33MG;50MG;33.33MG TABLET, EXTENDED RELEASE;ORAL Discontinued

92. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

CN107428760B BAYER HEALTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

CN107428760A BAYER HEALTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

EP3218380A1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380B1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Prescription

93. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

CN107428760B BAYER HLTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

CN107428760A BAYER HLTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

EP3218380A1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380B1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE;ORAL Prescription
EQ 100MG BASE CAPSULE;ORAL Prescription

94. Drug name - VIVLODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649318 ZYLA Formulation of meloxicam Mar, 2035

(12 years from now)

US9808468 ZYLA Formulation of meloxicam Mar, 2035

(12 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam; management of osteoarthritis pain by administering 5 mg of meloxicam

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG CAPSULE;ORAL Discontinued
10MG CAPSULE;ORAL Discontinued

95. Drug name - VYNDAMAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9770441 FOLDRX PHARMS Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Aug, 2035

(12 years from now)

EP3191461B1 FOLDRX PHARMS Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Aug, 2035

(12 years from now)

EP3191461A1 FOLDRX PHARMS Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Aug, 2035

(12 years from now)

Drugs and Companies using TAFAMIDIS ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
61MG CAPSULE;ORAL Prescription

96. Drug name - XHANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300229 OPTINOSE US INC Nasal delivery devices Jul, 2035

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.093MG SPRAY, METERED;NASAL Prescription

97. Drug name - XPOVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519139 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(12 years from now)

CN107072992B KARYOPHARM THERAPS Polymorphs Of
Aug, 2035

(12 years from now)

CN107072992A KARYOPHARM THERAPS Polymorph
Aug, 2035

(12 years from now)

EP3180331A1 KARYOPHARM THERAPS Polymorphs Of Selinexor
Aug, 2035

(12 years from now)

EP3180331B1 KARYOPHARM THERAPS Polymorphs Of Selinexor
Aug, 2035

(12 years from now)

Drugs and Companies using SELINEXOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

98. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912782 ANTARES PHARMA INC Needle assisted injection administration of testosterone compositions Feb, 2035

(12 years from now)

US10238662 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions Feb, 2035

(12 years from now)

US11191908 ANTARES PHARMA INC Syringe shock absorber for use in an injection device Oct, 2035

(13 years from now)

US9744302 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force Nov, 2035

(13 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
50MG/0.5ML (50MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
75MG/0.5ML (75MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
100MG/0.5ML (100MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

99. Drug name - ZEGALOGUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10442847 ZEALAND PHARMA Glucagon analogues
Feb, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

100. Drug name - ZERBAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds Aug, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL POWDER;INTRAVENOUS Prescription

101. Drug name - ZINGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358338 POWDER PHARMS Particle cassettes and processes therefor Apr, 2035

(12 years from now)

US9370622 POWDER PHARMS Devices and methods for delivering particles Sep, 2035

(13 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Treatment: Zingo is a powder intradermal system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action

Dosage: SYSTEM;INTRADERMAL

More Information on Dosage
Strength Dosage Availability
0.5MG SYSTEM;INTRADERMAL Prescription

102. Drug name - ZYNRELEF KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980886 HERON THERAPS INC Compositions of a polyorthoester and an organic acid excipient Apr, 2035

(12 years from now)

US9694079 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10098957 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US9801945 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10632199 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10213510 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US11083730 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US11083797 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

US10898575 HERON THERAPS INC Long-acting polymeric delivery systems Apr, 2035

(12 years from now)

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage
Strength Dosage Availability
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) SOLUTION, EXTENDED RELEASE;PERIARTICULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.